WO2024097598A1 - Triazines utiles comme inhibiteurs de la protéine réceptrice de type nod 3 - Google Patents
Triazines utiles comme inhibiteurs de la protéine réceptrice de type nod 3 Download PDFInfo
- Publication number
- WO2024097598A1 WO2024097598A1 PCT/US2023/077986 US2023077986W WO2024097598A1 WO 2024097598 A1 WO2024097598 A1 WO 2024097598A1 US 2023077986 W US2023077986 W US 2023077986W WO 2024097598 A1 WO2024097598 A1 WO 2024097598A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triazin
- methyl
- trifluoromethyl
- alkyl
- pyrrolo
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 17
- 102000012064 NLR Proteins Human genes 0.000 title description 7
- 108091005686 NOD-like receptors Proteins 0.000 title description 7
- 150000003918 triazines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 230
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 115
- 150000003839 salts Chemical class 0.000 claims abstract description 81
- 201000010099 disease Diseases 0.000 claims abstract description 59
- 208000035475 disorder Diseases 0.000 claims abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 45
- 230000002265 prevention Effects 0.000 claims abstract description 19
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 12
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 12
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 12
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims abstract 4
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract 4
- -1 hexahydro-2H-cyclopenta[b][1,4]oxazepine Chemical compound 0.000 claims description 374
- 125000000217 alkyl group Chemical group 0.000 claims description 338
- 125000001424 substituent group Chemical group 0.000 claims description 333
- 229910052736 halogen Inorganic materials 0.000 claims description 184
- 150000002367 halogens Chemical class 0.000 claims description 184
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 239000001257 hydrogen Substances 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 70
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 62
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 28
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 20
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 14
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 14
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims description 14
- 208000027866 inflammatory disease Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- LATHDVDCFBYVBB-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-pyrrolo[2,3-c]pyridine Chemical compound C1CNCC2NCCC21 LATHDVDCFBYVBB-UHFFFAOYSA-N 0.000 claims description 11
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- 230000002757 inflammatory effect Effects 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- ADKDJHASTPQGEO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole Chemical compound C1CNC2CCCC21 ADKDJHASTPQGEO-UHFFFAOYSA-N 0.000 claims description 9
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 claims description 9
- FTUSZJTUFHXUPG-UHFFFAOYSA-N 1,2,3,3a,4,5-hexahydropyrrolo[2,3-c]pyrrole Chemical compound C1NC=C2NCCC21 FTUSZJTUFHXUPG-UHFFFAOYSA-N 0.000 claims description 9
- WJWHNTAKUNTHFX-UHFFFAOYSA-N 1-azabicyclo[3.2.0]heptane Chemical compound C1CCC2CCN21 WJWHNTAKUNTHFX-UHFFFAOYSA-N 0.000 claims description 9
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 claims description 9
- KSCPLKVBWDOSAI-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydro-1h-pyrrolo[3,4-b]pyridine Chemical compound N1CCCC2CNCC21 KSCPLKVBWDOSAI-UHFFFAOYSA-N 0.000 claims description 9
- FVHPPCBSLJVBQR-UHFFFAOYSA-N 2,3,4,4a,5,6,7,7a-octahydrocyclopenta[b][1,4]oxazine Chemical compound N1CCOC2CCCC21 FVHPPCBSLJVBQR-UHFFFAOYSA-N 0.000 claims description 9
- FHYZKKQMVYRORH-UHFFFAOYSA-N O1CCC2NCCC=C21 Chemical compound O1CCC2NCCC=C21 FHYZKKQMVYRORH-UHFFFAOYSA-N 0.000 claims description 9
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 9
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 9
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 claims description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000012659 Joint disease Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 abstract description 28
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 abstract description 16
- 201000005569 Gout Diseases 0.000 abstract description 10
- 208000002849 chondrocalcinosis Diseases 0.000 abstract description 10
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 abstract description 9
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 9
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 9
- 206010016654 Fibrosis Diseases 0.000 abstract description 7
- 206010019280 Heart failures Diseases 0.000 abstract description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract description 7
- 230000004761 fibrosis Effects 0.000 abstract description 7
- 208000008494 pericarditis Diseases 0.000 abstract description 7
- 230000009529 traumatic brain injury Effects 0.000 abstract description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 5
- 230000001629 suppression Effects 0.000 abstract description 2
- 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- 239000000203 mixture Substances 0.000 description 64
- 239000000543 intermediate Substances 0.000 description 62
- 235000019439 ethyl acetate Nutrition 0.000 description 61
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000011541 reaction mixture Substances 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 43
- 239000010410 layer Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 34
- 239000002904 solvent Substances 0.000 description 31
- 229920000728 polyester Polymers 0.000 description 29
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 26
- 239000010948 rhodium Substances 0.000 description 25
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- 108010034143 Inflammasomes Proteins 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 238000005160 1H NMR spectroscopy Methods 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 230000005526 G1 to G0 transition Effects 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 238000004808 supercritical fluid chromatography Methods 0.000 description 13
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 238000004007 reversed phase HPLC Methods 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 208000017169 kidney disease Diseases 0.000 description 10
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 206010064930 age-related macular degeneration Diseases 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 208000002557 hidradenitis Diseases 0.000 description 8
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 8
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 8
- 208000002780 macular degeneration Diseases 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108090000426 Caspase-1 Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 5
- 208000009525 Myocarditis Diseases 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 229910002666 PdCl2 Inorganic materials 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000000713 anti-steatotic effect Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 4
- 108090000171 Interleukin-18 Proteins 0.000 description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 208000022873 Ocular disease Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000003524 antilipemic agent Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 201000001981 dermatomyositis Diseases 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000010030 glucose lowering effect Effects 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229940045207 immuno-oncology agent Drugs 0.000 description 4
- 239000002584 immunological anticancer agent Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 206010028537 myelofibrosis Diseases 0.000 description 4
- 208000030613 peripheral artery disease Diseases 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 201000003274 CINCA syndrome Diseases 0.000 description 3
- 208000035690 Familial cold urticaria Diseases 0.000 description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 3
- 206010023421 Kidney fibrosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical compound C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 3
- SVKJOUIZQRKDAI-UHFFFAOYSA-N difluoromethanesulfinic acid;zinc Chemical compound [Zn].OS(=O)C(F)F.OS(=O)C(F)F SVKJOUIZQRKDAI-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 201000011461 pre-eclampsia Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000006010 pyroptosis Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000020431 spinal cord injury Diseases 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 3
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- YRAJNWYBUCUFBD-UHFFFAOYSA-N 2,2,6,6-tetramethylheptane-3,5-dione Chemical compound CC(C)(C)C(=O)CC(=O)C(C)(C)C YRAJNWYBUCUFBD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZGHGKMHQDHHJES-UHFFFAOYSA-N 2-[2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C(C)OCOC1=C(C(=CC(=C1)C(F)(F)F)C)B1OC(C(O1)(C)C)(C)C ZGHGKMHQDHHJES-UHFFFAOYSA-N 0.000 description 2
- IQOMAXUXLBWNHU-UHFFFAOYSA-N 2-[2-methoxy-6-methyl-4-(trifluoromethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound COC1=C(C(=CC(=C1)C(F)(F)F)C)B1OC(C(O1)(C)C)(C)C IQOMAXUXLBWNHU-UHFFFAOYSA-N 0.000 description 2
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 2
- ZWLIZCSTDUPRKB-UHFFFAOYSA-N 2-iodo-3-methyl-5-(trifluoromethyl)phenol Chemical compound IC1=C(C=C(C=C1C)C(F)(F)F)O ZWLIZCSTDUPRKB-UHFFFAOYSA-N 0.000 description 2
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- POFDPLRIXZIUOB-UHFFFAOYSA-N C(C)OCOC1=C(C(=CC(=C1)C(F)(F)F)C)I Chemical compound C(C)OCOC1=C(C(=CC(=C1)C(F)(F)F)C)I POFDPLRIXZIUOB-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100035904 Caspase-1 Human genes 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 2
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 108010026389 Gramicidin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101100337977 Mus musculus Gsdmd gene Proteins 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- 102000005583 Pyrin Human genes 0.000 description 2
- 108010059278 Pyrin Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003510 anti-fibrotic effect Effects 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 229940127226 anticholesterol agent Drugs 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 229960004905 gramicidin Drugs 0.000 description 2
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QCQJCNQXZJNWLW-UHFFFAOYSA-N tert-butyl 5-methoxy-2,3-dihydropyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C1=NC(OC)=CC2=C1N(C(=O)OC(C)(C)C)CC2 QCQJCNQXZJNWLW-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- PDJQCHVMABBNQW-MIXQCLKLSA-L (1z,5z)-cycloocta-1,5-diene;rhodium;dichloride Chemical compound [Cl-].[Cl-].[Rh].[Rh].C\1C\C=C/CC\C=C/1.C\1C\C=C/CC\C=C/1 PDJQCHVMABBNQW-MIXQCLKLSA-L 0.000 description 1
- 125000006560 (C1-C5)alkylcarbonylamino group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- WYCCNPHNTWRJEP-UHFFFAOYSA-N 1,2,3,6-tetrahydropyrrolo[2,3-c]pyridin-5-one Chemical compound O=c1cc2CCNc2c[nH]1 WYCCNPHNTWRJEP-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- UCDITZXDIDICJU-UHFFFAOYSA-N 1,6-dihydropyrrolo[2,3-c]pyridin-5-one Chemical compound C1=NC(O)=CC2=C1NC=C2 UCDITZXDIDICJU-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ORVPXPKEZLTMNW-UHFFFAOYSA-N 1h-indol-7-ol Chemical compound OC1=CC=CC2=C1NC=C2 ORVPXPKEZLTMNW-UHFFFAOYSA-N 0.000 description 1
- MVZMRLKZBVSRNM-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1H-imidazo[4,5-c]pyridine Chemical compound C1NC2CCNCC2N1 MVZMRLKZBVSRNM-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- GBBSAMQTQCPOBF-UHFFFAOYSA-N 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane Chemical compound CB1OB(C)OB(C)O1 GBBSAMQTQCPOBF-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- PUSZVWBYGSSEJV-UHFFFAOYSA-N 2-iodo-1-methoxy-3-methylbenzene Chemical compound COC1=CC=CC(C)=C1I PUSZVWBYGSSEJV-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BWJBVICFLRSNNM-UHFFFAOYSA-N 3-bromo-5-(trifluoromethyl)phenol Chemical compound OC1=CC(Br)=CC(C(F)(F)F)=C1 BWJBVICFLRSNNM-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- VOOZRDXCKRUKTQ-UHFFFAOYSA-N 3-methyl-5-(trifluoromethyl)phenol Chemical compound CC1=CC(O)=CC(C(F)(F)F)=C1 VOOZRDXCKRUKTQ-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical group CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OEPBVXQEVBURGC-UHFFFAOYSA-N 4-bromo-2-fluoro-1-(trifluoromethyl)benzene Chemical compound FC1=CC(Br)=CC=C1C(F)(F)F OEPBVXQEVBURGC-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- CCNJNELOBGXDFD-UHFFFAOYSA-N 5-methoxy-1h-pyrrolo[2,3-c]pyridine Chemical compound C1=NC(OC)=CC2=C1NC=C2 CCNJNELOBGXDFD-UHFFFAOYSA-N 0.000 description 1
- INPPAWCHJHNCAE-UHFFFAOYSA-N 5-methyl-1,2,4-triazine Chemical compound CC1=CN=NC=N1 INPPAWCHJHNCAE-UHFFFAOYSA-N 0.000 description 1
- OXICBLZZGPYUQZ-UHFFFAOYSA-N 6-bromo-2-fluoro-3-(trifluoromethyl)phenol Chemical compound BrC1=CC=C(C(=C1O)F)C(F)(F)F OXICBLZZGPYUQZ-UHFFFAOYSA-N 0.000 description 1
- FLMMACLWTFUFRQ-UHFFFAOYSA-N 6-methyl-1,2,3,3a,4,5,7,7a-octahydropyrrolo[2,3-c]pyridine Chemical group C1N(C)CCC2CCNC21 FLMMACLWTFUFRQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 101710139398 Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- PPXVLCXIWGHXOY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1C=CC=2C1=CN=C(C=2)OC Chemical compound C(C)(C)(C)OC(=O)N1C=CC=2C1=CN=C(C=2)OC PPXVLCXIWGHXOY-UHFFFAOYSA-N 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000021350 Caspase recruitment domains Human genes 0.000 description 1
- 108091011189 Caspase recruitment domains Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 229940127194 DGAT2 inhibitor Drugs 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101100117236 Drosophila melanogaster speck gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102100037387 Gasdermin-A Human genes 0.000 description 1
- 102100037388 Gasdermin-D Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 1
- 101001026276 Homo sapiens Gasdermin-A Proteins 0.000 description 1
- 101001026262 Homo sapiens Gasdermin-D Proteins 0.000 description 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000008852 Hyperoxaluria Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- IHJXVJYOQNKDMN-UHFFFAOYSA-N IC1=C(C=C(C=C1C)C(F)(F)F)OC Chemical compound IC1=C(C=C(C=C1C)C(F)(F)F)OC IHJXVJYOQNKDMN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 208000018501 Lymphatic disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 238000006161 Suzuki-Miyaura coupling reaction Methods 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZNOWREWTFBTJOP-UHFFFAOYSA-N [4-chloro-2-(methoxymethoxy)phenyl]boronic acid Chemical compound ClC1=CC(=C(C=C1)B(O)O)OCOC ZNOWREWTFBTJOP-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical class NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- LMRGIWYBLKXQGS-UHFFFAOYSA-M dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane methanesulfonate palladium(2+) 2-phenylaniline Chemical compound [Pd+2].CS([O-])(=O)=O.NC1=CC=CC=C1C1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 LMRGIWYBLKXQGS-UHFFFAOYSA-M 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000002952 image-based readout Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- KFOSBANHALBORK-UWVGGRQHSA-N tert-butyl (3aS,7aR)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound N1(CC[C@H]2[C@@H]1CNCC2)C(=O)OC(C)(C)C KFOSBANHALBORK-UWVGGRQHSA-N 0.000 description 1
- KFOSBANHALBORK-NXEZZACHSA-N tert-butyl (3ar,7as)-2,3,3a,4,5,6,7,7a-octahydropyrrolo[2,3-c]pyridine-1-carboxylate Chemical compound C1CNC[C@H]2N(C(=O)OC(C)(C)C)CC[C@H]21 KFOSBANHALBORK-NXEZZACHSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- BACKGROUND Inflammasomes function as central signalling hubs of the innate immune system. They are multi-protein complexes assembled after activation of intracellular pattern recognition receptors (PRRs) by a variety of pathogen-associated molecular patterns (PAMPs) or danger- associated molecular patterns (DAMPs).
- PRRs pattern recognition receptors
- PAMPs pathogen-associated molecular patterns
- DAMPs danger- associated molecular patterns
- inflammasomes can be formed by nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and Pyrin and HIN200-domain-containing proteins (Van Opdenbosch N and Lamkanfi M. Immunity, 2019 Jun 18;50(6):1352-1364).
- NOD nucleotide-binding oligomerization domain
- NLRs nucleotide-binding oligomerization domain
- HIN200-domain-containing proteins Van Opdenbosch N and Lamkanfi M. Immunity, 2019 Jun 18;50(6):1352-1364.
- Inflammasome activation triggers a cascade of events that releases pro- inflammatory cytokines, and promotes an inflammatory form of cell death called pyroptosis induced by the activation of Gasdermin.
- Pyroptosis is a unique form of inflammatory cell death that leads to the release of not only cytokines but also other intracellular components that promote a broader immune
- inflammasome activation is a major regulator of the inflammatory cascade.
- the (NOD)-like receptor protein 3 (NLRP3) inflammasome is the most well-studied of all the inflammasomes. NLRP3 can be activated by numerous stimuli including environmental crystals, pollutants, host-derived DAMPs and protein aggregates (Tartey S and Kanneganti TD. Immunology, 2019 Apr;l56(4):329-338).
- Danger- associated molecular patterns that engage NLRP3 include uric acid and cholesterol crystals that cause gout and atherosclerosis, amyloid-P fibrils that are neurotoxic in Alzheimer's disease, and asbestos particles that cause mesothelioma (Kelley et al., Int J Mol Sci, 2019 Jul 6;20(13)). Additionally, NLRP3 is activated by infectious agents, such as vibrio cholerae, fungal pathogens, such as Aspergillus Jumigatus and Candida albicans, adenoviruses, influenza A virus and SARS-CoV-2 (Tartey and Kanneganti, 2019 (see above); Fung et al.
- infectious agents such as vibrio cholerae, fungal pathogens, such as Aspergillus Jumigatus and Candida albicans, adenoviruses, influenza A virus and SARS-CoV-2 (Tartey and Kanneganti, 2019 (see above); Fung et
- the NOD-like receptor protein 3 is a protein-coding gene that encodes a protein consisting of a N- terminal pyrin domain, a nucleotide-binding site domain (NBD), and a leucine-rich repeat (LRR) motif on the C-terminal (Inoue et al., Immunology, 2013, 139, 11-18; Sharif et al., Nature, 2019 Jun; 570(7761):338-343).
- NLRP3 In response to sterile inflammatory danger signals PAMPs or DAMPs, NLRP3 interacts with the adaptor protein, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and with the protease caspase-1 to form the NLRP3 inflammasome.
- ASC caspase recruitment domain
- procaspase-1 Upon activation, procaspase-1 undergoes autoproteolysis and cleaves gasdermin D (Gsdmd) to produce the N-terminal Gsdmd molecule that leads to pore-formation in the plasma membrane and results in a lytic form of cell death called pyroptosis.
- Gsdmd gasdermin D
- caspase-1 cleaves the pro-inflammatory cytokines pro-IL-I ⁇ and pro-IL-18 to allow release of its biological active form (Kelley et al., 2019 - see above).
- the NLRP3 inflammasome activation results in the release of the inflammatory cytokines IL-l ⁇ (interleukin-I ⁇ ) and IL-18 (interleukin-18), which when dysregulated can lead to a number of diseases.
- Dysregulation of the NLRP3 inflammasome or its downstream mediators are associated with numerous immune diseases, inflammatory diseases, auto-immune diseases and auto- inflammatory diseases.
- Activation of the NLRP3 inflammasome has been linked to the following diseases and disorders: Cryopyrin-associated Periodic Syndromes; sickle cell disease; systemic lupus erythematosus; allodynia; graft versus host disease; hepatic disorders including non- alcoholic steatohepatitis (NASH), chronic liver disease, viral hepatitis, alcoholic steatohepatitis, and alcoholic liver disease; inflammatory bowel diseases including Crohn's disease and ulcerative colitis; inflammatory joint disorders including gout, pseudogout, arthropathy, osteoarthritis, rheumatoid arthritis; additional rheumatic diseases including dermatomyositis, Still’s disease, and juvenile idiopathic arthritis.
- Cryopyrin-associated Periodic Syndromes Cryopyrin-associated Periodic Syndromes
- sickle cell disease systemic lupus erythematosus
- allodynia graft versus
- kidney related diseases including hyperoxaluria, lupus nephritis, hypertensive nephropathy, hemodialysis related inflammation, diabetic nephropathy,anddiabetic kidney disease and other inflammatory diseases
- hyperoxaluria lupus nephritis
- hypertensive nephropathy hemodialysis related inflammation
- diabetic nephropathy anddiabetic kidney disease and other inflammatory diseases
- neuroinflammation-related disorders such as brain infection, acute injury, multiple sclerosis, amyotrophic lateral sclerosis and additional neurodegenerative diseases such as Parkinsons and Alzheimer's disease have also been linked to NLRP3 inflammasome activation (Sarkar et al., NPJ Parkinsons Dis, 2017 Oct 17;3:30).
- Cardiovascular and metabolic disorders such as atherosclerosis, type I and type II diabetes and diabetes complications including nephropathy and retinopathy, peripheral artery disease, acute heart failure and hypertension have been associated to NLRP3 (Ridker et al., CANTOS Trial Group.
- NLRP3 associated skin diseases include wound healing and scar formation; inflammatory skin diseases such as acne, atopic dermatitis, hidradenitis suppurativa and psoriasis (Kelly et al., Br J Dermatol, 2015 Dec;l 73(6)).
- NLRP3 inflammasome activity has also been linked to respiratory conditions such as asthma, sarcoidosis, acute respiratory distress syndrome, Severe Acute Respiratory Syndrome (SARS) (Nieto-Torres et al., Virology, 2015 Nov;485:330-9)); and ocular diseases including age-related macular degeneration (AMD) and diabetic retinopathy (Doyle et al., Nat Med, 2012 May;18(5):791-8).
- SARS Severe Acute Respiratory Syndrome
- Cancers linked to NLRP3 include myeloproliferative neoplasms, leukemias, myelodysplastic syndromes, myelofibrosis, lung cancer and colon cancer (Ridker et al., Lancet, 2017 Oct 21;390(10105): 1833-1842; Derangere et al., Cell Death Differ.2014 Dec;21(12): 1914-24; Basiorka et al., Lancet Haematol, 2018 Sep;5(9): e393-e402, Zhang et al., Hum Immunol, 2018 Jan;79(1):57-62). Immune diseases and inflammatory disorders are typically difficult to diagnose or treat efficiently and effectively.
- NLRP3 inhibitors are disclosed in the following publications: Nat.2022, 1; Cell.2021, 184, 1; J. Mol. Biol.2021, 433, 167308; J. Med. Chem.2021, 64, 101; Nat. Chem. Biol.2019, 15, 556; Nat.2019, 570, 338; Nat. Chem.
- NLRP3 inhibitors including WO 2021/239885, WO 2021/209552, WO 2021/209539, WO 2021/193897, WO 2020/018975, WO 2020/037116, WO 2020/021447, WO 2020/010143, WO 2019/079119, WO 2019/0166621, WO 2019/121691, WO 2019/034696, WO 2019/034697, WO 2019/034693, WO 25602 2019/034692, WO 2019/034690, WO 2019/034688, WO 2019/034686, WO 2019/008025, WO 2019/008029, WO 2019/023145, WO 2019/023147, WO 2019/025467, WO 2018/167468, WO 2018/015445, WO 2017/184746, WO 2017/184735, WO 2017/184623, WO 2017/184604, WO 2017/184624, WO 2017/140778,
- novel compounds of structural formula I are inhibitors of NOD- like receptor protein 3 (NLRP3) and may be useful in the treatment and prevention of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, gout, pseudogout (chondrocalcinosis), cryopyrin-associated periodic syndromes (CAPS), NASH, fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer’s Disease, Parkinson’s Disease and traumatic brain injury.
- pharmaceutical compositions comprising the compounds of structural formula I and a pharmaceutically acceptable carrier.
- the present disclosure also relates to methods for the treatment, management, prevention, alleviation, amelioration, suppression or control of disorders, diseases, and conditions that may be responsive to inhibition of the NLRP3 receptor in a subject in need thereof by administering the compounds and pharmaceutical compositions of the present disclosure.
- the present disclosure also relates to the use of compounds of the present disclosure for manufacture of a medicament useful in treating diseases, disorders and conditions that may be responsive to the inhibition of the NLRP3 receptor.
- the present disclosure is also concerned with treatment or prevention of these diseases, disorders and conditions by administering the compounds of the present disclosure in combination with a therapeutically effective amount of another agent that may be useful to treat the disease, disorder and condition. Further disclosed are processes for preparing the compounds of structural formula I.
- novel compounds of structural formula I Y X R 2 R 1 or a pharmaceutically acceptable salt
- X is selected from the group: (1) CR 3 , and (2) N
- Y is selected from the group: (1) CR 4 , and (2) N, provided that one of X and Y is N
- R 1 is selected from the group: ( 1) -C 3-12 cycloalkyl, (2) -C 3-12 cycloalkenyl, and (3) -C 2-12 cycloheteroalkyl, wherein R 1 is unsubstituted or substituted with one to five substituents selected from R a
- R 2 is selected from the group: (1) aryl, and (2) heteroaryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b
- R 3 is selected from the group: (1) hydrogen, ( 2) -C 1-6 alkyl, (3) -C 3-6 cycloalkyl, (4) -C 2-6 cyclohe
- X is selected from the group: CR 3 , and N.
- X is CR 3 .
- X is N.
- Y is selected from the group: CR 4 , and N, provided that one of X and Y is N.
- Y is N, provided that X is CR 3 .
- Y is N.
- Y is CR 4 , provided that X is N. In another embodiment, Y is CR 4 .
- R1 is selected from the group: -C 3-12 cycloalkyl, -C 3- 12 cycloalkenyl, and -C 2-12 cycloheteroalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a .
- R1 is selected from the group: -C 3-12 cycloalkyl, and -C 2- 12 cycloheteroalkyl, wherein R 1 is unsubstituted or substituted with one to five substituents selected from R a .
- R 1 is unsubstituted or substituted with one to four substituents selected from R a . In another subclass of this class, R 1 is unsubstituted or substituted with one to three substituents selected from R a .
- R1 is -C 3-12 cycloalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a . In a class of this embodiment, R 1 is unsubstituted or substituted with one to four substituents selected from R a . In another class of this embodiment, R 1 is unsubstituted or substituted with one to three substituents selected from R a .
- R1 is -C 3-12 cycloalkenyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a .
- R 1 is unsubstituted or substituted with one to four substituents selected from R a .
- R 1 is unsubstituted or substituted with one to three substituents selected from R a .
- R1 is -C 2-12 cycloheteroalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a .
- R 1 is unsubstituted or substituted with one to four substituents selected from R a . In another class of this embodiment, R 1 is unsubstituted or substituted with one to three substituents selected from R a .
- R 1 is selected from the group: pyrrolidine, piperidine, piperazine, morpholine, oxazepine, hexahydropyrrolo[3,4-b]pyrrole, octahydro-1H-pyrrolo[2,3- c]pyridine, octahydro-1H-pyrrolo[3,4-b]pyridine, octahydro-2H-pyrrolo[2,3-c]pyridine, octahydro-3H-pyrrolo[2,3-c]pyridine, octahydro-1H-indole, octa-hydro-2H-imidazo[4,5- c]pyridine, octahydrocyclopenta[b]pyrrole, octahydrocyclo-penta[c]pyrrole, octahydro-2H- pyrido[3,4-d][1,3]oxazine
- R 1 is unsubstituted or substituted with one to four substituents selected from R a . In another subclass of this class, R 1 is unsubstituted or substituted with one to three substituents selected from R a . In another class of this embodiment, R 1 is octahydro-1H-pyrrolo[2,3-c]pyridine, wherein R 1 is unsubstituted or substituted with one to five substituents selected from R a . In a subclass of this class, R 1 is unsubstituted or substituted with one to four substituents selected from R a .
- R 1 is unsubstituted or substituted with one to three substituents selected from R a .
- R 1 is 6-methyl-octahydro-1H- pyrrolo[2,3-c]pyridine.
- R 2 is selected from the group: aryl, and heteroaryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is selected from the group: phenyl, pyridine, benzothiophene, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is 25602 unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is unsubstituted.
- R 2 is substituted with one to three substituents selected from R b .
- R 2 is selected from the group: aryl, and heteroaryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is selected from the group: phenyl, pyridine, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b . In another subclass of this class, R 2 is unsubstituted or substituted with one to three substituents selected from R b . In another subclass of this class, R 2 is unsubstituted. In another subclass of this class, R 2 is substituted with one to three substituents selected from R b . In another embodiment, R 2 is heteroaryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b . In a class of this embodiment, R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is selected from the group: pyridine, benzothiophene, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is unsubstituted.
- R 2 is substituted with one to three substituents selected from R b .
- R 2 is heteroaryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is selected from the group: pyridine, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is unsubstituted.
- R 2 is substituted with one to three substituents selected from R b .
- R 2 is aryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is phenyl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b .
- R 2 is unsubstituted or substituted with one to four substituents selected from R b .
- R 2 is unsubstituted or substituted with one to three substituents selected from R b .
- R 2 is unsubstituted.
- R 2 is substituted with one to three substituents selected from R b .
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, -C 2-6 cycloheteroalkyl, -OH, -C 1-6 alkyl-O-C 1-6 alkyl, -O-C 1-6 alkyl, -NReRf, wherein each alkyl, cycloalkyl and cycloheteroalkyl is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R 3 is selected from the group: h ydrogen, -C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, -OH, -O-C 1-6 alkyl, - NR e R f , wherein R 3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, -C 2-6 cycloheteroalkyl, OH, -O-C 1-6 alkyl, and -NReRf, wherein R3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, and -O-C 1-6 alkyl, wherein each R3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, OH, -O- C 1-6 alkyl,and -NR e R f , wherein R 3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R 3 is selected from the group: hydrogen, -CH 3 , OH, -OCH 3 , and -NH 2 .
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, -O-C 1- 6 alkyl, and -NR e R f , wherein R 3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R3 is selected from the group: hydrogen, -CH 3 , -OCH 3 , and -NH 2 .
- R 3 is hydrogen.
- R3 is selected from the group: hydrogen, -C 1-6 alkyl, -O-C 1- 6alkyl, and -NR e R f , wherein R 3 is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R 3 is selected from the group: hydrogen, -CH 3 , -OCH 3 , and -NH 2 .
- R3 is -C 1-6 alkyl, wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R c .
- R 3 is unsubstituted or substituted with one to four substituents selected from R c .
- R 3 is unsubstituted or substituted with one to three substituents selected from R c .
- R 3 is -CH 3 .
- R4 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, -C 2-6 cycloheteroalkyl, -OH, -O-C 1-6 alkyl, -C 1-6 alkyl-O-C 1-6 alkyl, and -NReRf, wherein each R 4 is unsubstituted or substituted with one to five substituents selected from R d . In a class of this embodiment, R 4 is unsubstituted or substituted with one to four substituents selected from R d . In another class of this embodiment, R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, -C 2-6 cycloheteroalkyl, -OH, -O-C 1-6 alkyl, -C 1-6 alkyl-O-C 1-6 alkyl, and -NReRf, wherein R 4 is unsubstituted or substituted with one to five substituents selected from R d . In a class of this embodiment, R 4 is unsubstituted or substituted with one to four substituents selected from R d . In another class of this embodiment, R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R 4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, -OH, -OCH 3 , -OCHF 2 , and -NH 2 , wherein R4 is unsubstituted or substituted with one to five substituents selected from R d . In a subclass of this class, R 4 is unsubstituted or substituted with one to four substituents selected from R d . In another subclass of this class, R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, -OH, -O-C 1-6 alkyl, and -NReRf, wherein R4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, -OH, -OCH 3 , -OCHF 2 , and -NH 2 , wherein R4 is unsubstituted or substituted with one to five substituents selected from R d . In a subclass of this class, R 4 is unsubstituted or substituted with one to four substituents selected from R d . In another subclass of this class, R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, -OH, -OCH 3 , - OCHF 2 , and -NH 2 .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , cyclopropyl, and -OCH 3 , wherein R4 is unsubstituted or substituted 25602 with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , cyclopropyl, and - OCH 3 .
- R4 is selected from the group: hydrogen, -C 1-6 alkyl, -C 3- 6 cycloalkyl, and -O-C 1-6 alkyl, wherein each R4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, - OCH 3 , and -OCHF 2 , wherein each R4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R 4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, -OCH 3 , and -OCHF 2 .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , cyclopropyl, and -OCH 3 , wherein each R 4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 , -CHF 2 , cyclopropyl, and -OCH 3 .
- R4 is selected from the group: -C 1-6 alkyl, -C 3-6 cycloalkyl, and -O-C 1-6 alkyl, wherein R4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R4 is selected from the group: -CH 3 , -CHF 2 , -CHF 3 , cyclopropyl, -OCH 3 , and -OCHF 2 , wherein R 4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R 4 is selected from the group: -CH 3 , -CHF 2 , - CHF 3 , cyclopropyl, -OCH 3 , and -OCHF 2 .
- R4 is selected from the group: -CH 3 , -CHF 2 , cyclopropyl, and -OCH 3 , wherein R4 is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R 4 is selected from the group: -CH 3 , -CHF 2 , cyclopropyl, and - OCH 3 .
- R4 is selected from the group: hydrogen, and -C 1-6 alkyl, wherein each R 4 is unsubstituted or substituted with one to five substituents selected from R d .
- R4 is selected from the group: hydrogen, -CH 3 .and -CHF 2 .
- R 4 is selected from the group: hydrogen, and -CH 3 .
- R4 is -C 1-6 alkyl, wherein each alkyl is unsubstituted or substituted with one to five substituents selected from R d .
- R 4 is unsubstituted or substituted with one to four substituents selected from R d .
- R 4 is unsubstituted or substituted with one to three substituents selected from R d .
- R 4 is selected from the group: -CH 3 , -CHF 2 , and - CHF 3 .
- R4 is selected from the group: -CH 3 , and -CHF 2 .
- R4 is -CH 3 .
- R 4 is hydrogen.
- each R a is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2- 6 cycloheteroalkyl, aryl, heteroaryl, -C(O)C 1-6 alkyl, –C 1-6 alkyl-aryl, –C 1-6 alkyl-heteroaryl, – C 1-6 alkyl-C 3-6 cycloalkyl, –C 1-6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) p -O-C 1-6 alkyl, –(CH 2 ) p - O-C 3-6 cycloalkyl, —(CH 2 ) p -O-C 1-6
- R a is 25602 unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1- 6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- each R a is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2- 6 cycloheteroalkyl, aryl, heteroaryl, -C(O)C 1-6 alkyl, –C 1-6 alkyl-aryl, –C 1-6 alkyl-heteroaryl, – C 1-6 alkyl-C 3-6 cycloalkyl, –C 1-6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) p -O-C 1-6 alkyl, –(CH 2 ) p - O-C 3-6 cycloalkyl, –(CH 2 ) p -O-C 2-6 cycloheteroalkyl, –(CH 2 )
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF3, OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- each R a is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, - C(O)C 1-6 alkyl, –C 1-6 alkyl-C 3-6 cycloalkyl, –C 1-6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) p -O-C 1- 6 alkyl, –(CH 2 ) p -O-C 3-6 cycloalkyl, –(CH 2 ) p -O-C 2-6 cycloheteroalkyl, -C 1-6 alkyl-S(O) r Rg, - C 1-6 alkyl-N(Rh)C(O)Ri ,
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF3, OH, C1- 6 alkyl, and -OC 1-6 alkyl.
- each R a is independently selected from the group: -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C(O)C 1-6 alkyl, - (CH 2 ) p -O-C 1-6 alkyl, -C 1-6 alkyl-S(O) r Rg, -C 1-6 alkyl-N(Rh)C(O)Ri , -N(Rh)C(O)Ri , -N(Rh)2, - - a unsubstituted or substituted with one to five substituents selected from: halogen, CF3, OH, C1- 6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl. In another class of this embodiment, R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- each R a is independently selected from the group: -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C(O)C 1-6 alkyl, -C 1- 6 alkyl-N(R h )C(O)R i , -N(R h )C(O)R i , -N(R h )2, and -C(O)R i , wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1- 6alkyl.
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF 3 , OH, C 1- 6alkyl, and -OC1-6alkyl.
- each R a is independently selected from the group: -OH, oxo, F, -SO 2 CH 3 , -CD 3 , -CH 3 , -CH 2 CH 3 , -CH 2 F, -CF 2 H, -CH 2 OH, - CH(OH)CH 3 , -OCH 3 , cyclopropyl, cyclopropyl-OH, -NH 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , - CH 2 NHC(O)CH 3 , -C(O)NH 2 , and -C(O)CH 3 .
- each Ra is independently selected from the group: -OH, oxo, F, -SO 2 CH 3 , -CD 3 , -CH 3 , -CH 2 CH 3 , -CH 2 F, -CF 2 H, -CH 2 OH, -CH(OH)CH 3 , -OCH 3 , cyclopropyl-OH, -NH 2 , -N(CH 3 ) 2 , -NHC(O)CH 3 , - CH 2 NHC(O)CH 3 , -C(O)NH 2 , and -C(O)CH 3 .
- each R a is independently selected from the group: -OH, oxo, halogen, -C 1-6 alkyl, -O-C 1-6 alkyl, and -C(O)C 1-6 alkyl, wherein each Ra is unsubstituted or substituted with one to six substituents selected from halogen, CF3, OH, C1-6alkyl, and -OC1- 6 alkyl.
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl. In another class of this embodiment, R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF 3 , OH, C 1- 6alkyl, and -OC1-6alkyl.
- each R a is independently selected from the group: -OH, oxo, halogen, -C 1-6 alkyl, and -O-C 1-6 alkyl, wherein each Ra is unsubstituted or substituted with one to six substituents selected from halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF3, OH, C1- 6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- each R a is independently selected from the group: -OH, oxo, F, -CD 3 , -CH 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each Ra is independently selected from the group: CN, -OH, oxo, F, -CH 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each R a is independently selected from the group: halogen and - C 1-6 alkyl, wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1- 6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- each Ra is independently selected from the group: F, -CD 3 , -CH 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each R a is independently selected from the group: F, -CH 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each Ra is independently selected from the group: F and -CH 3 .
- each R a is -C 1-6 alkyl, wherein each R a is unsubstituted or substituted with one to six substituents selected from halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1- 6alkyl.
- R a is unsubstituted or substituted with one to five substituents selected from: halogen, CF 3 , OH, C 1-6 alkyl, and -OC 1-6 alkyl.
- R a is unsubstituted or substituted with one to four substituents selected from: halogen, CF3, OH, C1-6alkyl, and -OC1-6alkyl.
- R a is unsubstituted or substituted with one to three substituents selected from: halogen, CF 3 , OH, C 1- 6 alkyl, and -OC 1-6 alkyl.
- each R a is independently selected from the group: -CH 3 , -CD 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each Ra is independently selected from the group: -CH 3 , -CH 2 CH 3 , and -CH(OH)CH 3 .
- each R a is -CH 3 .
- each R b is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, aryl, heteroaryl, –C 1-6 alkyl-aryl, –C 1-6 alkyl-heteroaryl, –C 1-6 alkyl-C 3-6 cycloalkyl, –C 1- 6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) q -O-C 1-6 alkyl, –(CH 2 ) q -O-C 3-6 cycloalkyl, –(CH 2 ) q -O- C 2-6 cycloheteroalkyl, –(CH 2 ) q -O-aryl, –(CH 2
- Rb is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1- 6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to six substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one 25602 to three substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- each R b is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, – C 1-6 alkyl-aryl, –C 1-6 alkyl-heteroaryl, –C 1-6 alkyl-C 3-6 cycloalkyl, –C 1-6 alkyl-C 2- 6 cycloheteroalkyl, -(CH 2 ) q -O-C 1-6 alkyl, –(CH 2 ) q -O-C 3-6 cycloalkyl, –(CH 2 ) q -O-C 2- 6 cycloheteroalkyl, -OC 1-6 alkyl-C 3-6 cycloalkyl, -OC 1-6 alkyl-C
- Rb is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1- 6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, and -OH.
- each R b is independently selected from the group: CN, -OH, oxo, halogen, –S(O) 2 C 1-6 alkyl, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, – C 1-6 alkyl-C 3-6 cycloalkyl, –C 1-6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) q -O-C 1-6 alkyl, –(CH 2 ) q - O-C 3-6 cycloalkyl, –(CH 2 ) q -O-C 2-6 cycloheteroalkyl, -OC 1-6 alkyl-C 3-6 cycl
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to six substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to three substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- each R b is independently selected from the group: CN, -OH, oxo, halogen, -C 1-6 alkyl, -O-C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, –C 1-6 alkyl-C 3- 6 cycloalkyl, –C 1-6 alkyl-C 2-6 cycloheteroalkyl, -(CH 2 ) q -O-C 1-6 alkyl, -N(Rk)2, and -C(O)RL, wherein each R b is unsubstituted or substituted with one to six substituents selected from halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 ,
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to six substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. In another class of this embodiment, R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- each R b is independently selected from the group: -OH, halogen, -C 1-6 alkyl, -O-C 1-6 alkyl, and -C 3-6 cycloalkyl, wherein each Rb is unsubstituted or substituted with one to six substituents selected from halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , - C 1-6 alkyl, and -OC 1-6 alkyl.
- each Rb is independently selected from the group: -OH, F, Cl, -CH 3 , -CF 3 , -OCHF 2 , -OCF 3 , and cyclopropane, wherein each Rb is unsubstituted or substituted with one to six substituents selected from halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- each Rb is independently selected from the group: -OH, F, Cl, -CH 3 , -CF 3 , -OCHF 2 , -OCF 3 , and cyclopropane.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1- 6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to six substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to three substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- each R b is independently selected from the group: -OH, halogen, and -C 1-6 alkyl, wherein each Rb is unsubstituted or substituted with one to six substituents selected from halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- R b is unsubstituted or substituted with one to four substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and - OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to three substituents selected from: halogen, -OH, CF 3 , OCF 3 , CN, CH 2 CF 3 , CF 2 CH 3 , -C 1-6 alkyl, and -OC 1-6 alkyl.
- Rb is unsubstituted or substituted with one to six substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- R b is unsubstituted or substituted with one to five substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to four substituents selected from: halogen, and -OH. In a subclass of this class, R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH. another class of this embodiment, R b is unsubstituted or substituted with one to three substituents selected from: halogen, and -OH.
- R b is unsubstituted or substituted with one to six substituents selected from: F, and -OH.
- Rb is selected from the group: halogen, -OH, and -C 1-6 alkyl.
- Rb is selected from the group: F, Cl, -OH, -CH 3 , -CF 3 , -OCF 3 , and - OCHF 2 .
- R b is selected from the group: Cl, -OH, -CH 3 , - CF 3 , and -OCHF 2 .
- each Rc is independently selected from the group: -C 1-6 alkyl, OH, halogen, and -OC 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three halogens.
- halogen is F.
- R c is selected from the group: -C 1-6 alkyl, OH, and halogen, wherein alkyl is unsubstituted or substituted with one to three halogens.
- halogen is F.
- Rc is selected from the group: -C 1-6 alkyl and halogen, wherein alkyl is unsubstituted or substituted with one to three halogens. In a subclass of this class, halogen is F. In another class of this embodiment, Rc is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three halogens. In a subclass of this class, halogen is F. In another class of this embodiment, R c is halogen. In a subclass of this class, R c is F.
- each R d is independently selected from the group: -C 1-6 alkyl, OH, halogen, and -OC 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three halogens.
- halogen is F.
- R d is selected from the group: -C 1-6 alkyl, OH, and halogen, wherein alkyl is unsubstituted or substituted with one to three halogens.
- halogen is F.
- Rd is selected from the group: -C 1-6 alkyl and halogen, wherein alkyl is unsubstituted or substituted with one to three halogens. In a subclass of this class, halogen is F. In another class of this embodiment, Rd is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three halogens. In a subclass of this class, halogen is F. In another class of this embodiment, R d is halogen. In a subclass of this class, R d is F. In another embodiment, each R e is independently selected from the group: hydrogen, and -C 1-6 alkyl.
- Re is -C 1-6 alkyl.
- R e is hydrogen.
- each R f is independently selected from the group: hydrogen, and -C 1-6 alkyl.
- Rf is -C 1-6 alkyl.
- R f is hydrogen.
- each Rg is independently selected from the group: -C 1-6 alkyl, - C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, and -NReRf, wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: - CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rg is independently 25602 selected from the group: -C 1-6 alkyl, -C 3-6 cycloalkyl, and -NReRf, wherein alkyl and cycloalkyl are unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R g is independently selected from the group: -C 1-6 alkyl, and -NR e R f , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rg is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl. In another class of this embodiment, each Rg is -C 1-6 alkyl.
- each R h is independently selected from the group: hydrogen, - C 1-6 alkyl, -C 3-6 cycloalkyl, and -C 2-6 cycloheteroalkyl, wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: - CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rh is independently selected from the group: hydrogen, -C 1-6 alkyl, and -C 3-6 cycloalkyl, wherein alkyl and cycloalkyl are unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rh is independently selected from the group: hydrogen, and -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R h is independently selected from the group: hydrogen and -CH 3 .
- each R h is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rh is -C 1-6 alkyl.
- each R h is hydrogen.
- each R i is independently selected from the group: hydrogen, -C 1- 6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, and -NReRf, wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Ri is independently selected from the group: hydrogen, -C 1-6 alkyl, -C 3-6 cycloalkyl, and -NReRf, wherein alkyl, and cycloalkyl are unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Ri is independently 25602 selected from the group: hydrogen, -C 1-6 alkyl, and -NR e R f , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R i is -NR e R f .
- each R i is -NH2.
- each R i is independently selected from the group: hydrogen, and -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Ri is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Ri is -C 1- 6 alkyl.
- each R i is hydrogen.
- each R j is independently selected from the group: -C 1-6 alkyl, - C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, and -NReRf, wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: - CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R j is independently selected from the group: -C 1-6 alkyl, -C 3-6 cycloalkyl, and -NReRf, wherein alkyl, and cycloalkyl are unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rj is independently selected from the group: -C1-6alkyl, and -NR e R f , wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R j is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl. In another class of this embodiment, each Rj is -C 1-6 alkyl.
- each R k is independently selected from the group: hydrogen, - C 1-6 alkyl, -C 3-6 cycloalkyl, and -C 2-6 cycloheteroalkyl, wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: - CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rk is independently selected from the group: hydrogen, -C 1-6 alkyl, and -C 3-6 cycloalkyl, wherein alkyl and cycloalkyl are unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rk is independently selected from the group: hydrogen, and -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted 25602 with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each Rk is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: -CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R k is -C 1-6 alkyl.
- each R k is hydrogen.
- each R L is independently selected from the group: hydrogen, - C 1-6 alkyl, -C 3-6 cycloalkyl, -C 2-6 cycloheteroalkyl, and -NReRf, wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each RL is independently selected from the group: hydrogen, -C 1-6 alkyl, and -NR e R f , wherein alkyl, cycloalkyl and cycloheteroalkyl are unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each RL is independently selected from the group: hydrogen, and -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each R L is -C 1-6 alkyl, wherein alkyl is unsubstituted or substituted with one to three substituents selected from: CF 3 , halogen, OH and -OC 1-6 alkyl.
- each RL is -C 1-6 alkyl.
- each R L is hydrogen.
- p is 0, 1, 2, 3, 4, 5 or 6.
- p is 0, 1, 2, 3, 4, or 5.
- p is 1, 2, 3, 4, 5 or 6.
- p is 1, 2, 3, 4 or 5.
- p is 0, 1, 2, 3, or 4.
- p is 1, 2, 3, or 4.
- p is 0, 1, 2, or 3.
- p is 0, 1, 2, or 3.
- p is 1, 2, or 3. In another embodiment, p is 0, 1 or 2. In another embodiment, p is 1 or 2. In another embodiment, p is 0. In another embodiment, p is 1. In another embodiment, p is 2. In another embodiment, p is 3. In another embodiment, p is 4. In another embodiment, p is 5. In another embodiment, p is 6. In another embodiment, q is 0, 1, 2, 3, 4, 5 or 6. In another embodiment, q is 0, 1, 2, 3, 4, or 5. In another embodiment, q is 1, 2, 3, 4, 5 or 6. In another embodiment, q is 1, 2, 3, 4 or 5. In another embodiment, q is 0, 1, 2, 3, or 4. In another embodiment, q is 0, 1, 2, or 3. In another embodiment, q is 1, 2, or 3. In another embodiment, q is 1, 2, or 3. In another embodiment, q is 1, 2, or 3. In another embodiment, q is 1, 2, or 3.
- q is 0, 1 or 2. In another embodiment, q is 1 or 2. In another embodiment, q is 0. In another 25602 embodiment, q is 1. In another embodiment, q is 2. In another embodiment, q is 3. In another embodiment, q is 4. In another embodiment, q is 5. In another embodiment, q is 6. In another embodiment, r is 0, 1 or 2. In another embodiment, r is 1 or 2. In another embodiment, r is 0. In another embodiment, r is 1. In another embodiment, r is 2. In another embodiment, s is 0, 1 or 2. In another embodiment, s is 1 or 2. In another embodiment, s is 0. In another embodiment, s is 1. In another embodiment, s is 2. Also provided are compounds of structural formula Ia: , or a salt thereof.
- the compound of structural formula I includes the compounds of structural formulas Ia and Ib, and pharmaceutically acceptable salts, hydrates and solvates thereof.
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R1 is -C 2-12 cycloheteroalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a ; R 2 is selected from the group: phenyl, pyridine, thiophene, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b ; R 4 is selected from the group: 25602 (1) hydrogen, ( 2) -C 1-6 alkyl, (3) -C 3-6 cycloalkyl, and (4) -O-C 1-6 alkyl, wherein each R 4 is unsubstituted or substituted with one
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R1 is -C 2-12 cycloheteroalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a ; R 2 is selected from the group: phenyl, pyridine, and benzofuran, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b ; R 4 is selected from the group: (1) hydrogen, ( 2) -C 1-6 alkyl, (3) -C 3-6 cycloalkyl, and (4) -O-C 1-6 alkyl, wherein each R 4 is unsubstituted or substituted with one to five substituents selected from R d ; and the other substituents as defined above; or a pharmaceutically acceptable salt thereof.
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R 1 is selected from the group: (1) pyrrolidine, (2) piperidine, 25602 (3) piperazine, (4) morpholine, (5) oxazepine, (6) hexahydropyrrolo[3,4-b]pyrrole, (7) octahydro-1H-pyrrolo[2,3-c]pyridine, (8) octahydro-1H-pyrrolo[3,4-b]pyridine, (9) octahydro-2H-pyrrolo[2,3-c]pyridine, (10) octahydro-3H-pyrrolo[2,3-c]pyridine, (11) octahydro-1H-indole, (12) octahydro-2H-imidazo[4,5-c]pyridine, (13) octahydrocyclopenta[b]pyrrole, (14) octa
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R 1 is selected from the group: (1) pyrrolidine, (2) piperidine, (3) piperazine, (4) morpholine, (5) oxazepine, (6) hexahydropyrrolo[3,4-b]pyrrole, (7) octahydro-1H-pyrrolo[2,3-c]pyridine, (8) octahydro-1H-pyrrolo[3,4-b]pyridine, (9) octahydro-2H-pyrrolo[2,3-c]pyridine, (10) octahydro-3H-pyrrolo[2,3-c]pyridine, (11) octahydro-1H-indole, (12) octahydro-2H-imidazo[4,5-c]pyridine, (13) octahydrocyclopenta[b]pyrrole, (14) octahydrocycl
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R1 is -C 2-12 cycloheteroalkyl, wherein R1 is unsubstituted or substituted with one to five substituents selected from R a ; R 2 is aryl, wherein R 2 is unsubstituted or substituted with one to five substituents selected from R b ; R 4 is selected from the group: (1) hydrogen, and ( 2) -C 1-6 alkyl, wherein each R 4 is unsubstituted or substituted with one to five substituents selected from R d ; and the other substituents are as defined above; or a pharmaceutically acceptable salt thereof.
- Another embodiment relates to compounds of structural formula I wherein: X is N; Y is CR 4 ; R 1 is selected from the group: (1) pyrrolidine, (2) piperidine, (3) piperazine, 25602 (4) morpholine, (5) oxazepine, (6) hexahydropyrrolo[3,4-b]pyrrole, (7) octahydro-1H-pyrrolo[2,3-c]pyridine, (8) octahydro-1H-pyrrolo[3,4-b]pyridine, (9) octahydro-2H-pyrrolo[2,3-c]pyridine, (10) octahydro-3H-pyrrolo[2,3-c]pyridine, (11) octahydro-1H-indole, (12) octahydro-2H-imidazo[4,5-c]pyridine, (13) octahydrocyclopenta[b]pyrrole, (14) octa
- Illustrative, but non-limiting, examples of compounds that are useful as inhibitors of the NLRP3 are the following compounds: (1) 2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)- 1,2,4-triazin-6-yl)-5-(trifluoromethyl)phenol; (2) (3aS,7aR)-1-(6-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)-5-methyl-1,2,4- triazin-3-yl)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridine; (3) 2-(5-methyl-3-((3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)- 1,2,4-triazin-6-yl)-5-(trifluoromethyl)phenol; (4) 4-flu
- Additional illustrative, but non-limiting, examples of compounds that are useful as inhibitors of the NLRP3 are the following compounds: 25602 (1) 2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)- 1,2,4-triazin-6-yl)-5-(trifluoromethyl)phenol; (2) (3aS,7aR)-1-(6-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)-5-methyl-1,2,4- triazin-3-yl)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridine; (3) 5-chloro-2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin- 1-yl)-1,2,4-triazin-6-yl)phenol; (4) 2-
- Additional illustrative, but non-limiting, examples of compounds that are useful as inhibitors of the NLRP3 are the following compounds: (1) 3,4-difluoro-2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3- c]pyridin-1-yl)-1,2,4-triazin-6-yl)phenol; (2) 3-fluoro-2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin- 1-yl)-1,2,4-triazin-6-yl)phenol; (3) 6-chloro-3-fluoro-2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3- c]pyridin-1-yl)-1,2,4-triazin-6-yl)phenol; (4) 4,5-difluoro
- stereoisomers including diastereoisomers, enantiomers, epimers, and mixtures of these may also have utility in treating NLRP3 mediated diseases.
- Synthetic methods for making the compounds are disclosed in the Examples shown below. Where synthetic details are not provided in the examples, the compounds are readily made by a person of ordinary skill in the art of medicinal chemistry or synthetic organic chemistry by applying the synthetic information provided herein. Where a stereochemical center is not defined, the structure represents a mixture of stereoisomers at that center. For such compounds, the individual stereoisomers, including enantiomers, diastereoisomers, and mixtures of these are also compounds of the disclosure.
- alkyl means saturated carbon chains which may be linear or branched or combinations thereof, unless the carbon chain is defined otherwise.
- alkenyl means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched, or combinations thereof, unless otherwise defined.
- alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2- butenyl, 2-methyl-2-butenyl, and the like.
- Alkynyl means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched, or combinations thereof, unless otherwise defined. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl and the like.
- Cycloalkyl means a saturated monocyclic, bicyclic, spirocyclic, fused or bridged carbocyclic ring, having a specified number of carbon atoms.
- Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- cycloalkyl is-C 3-12 cycloalkyl.
- cycloalkyl is selected from: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
- cycloalkyl is cyclopropyl.
- Cycloalkenyl means a monocyclic, bicyclic, spirocyclic, fused or bridged carbocyclic ring, having a specified number of carbon atoms with at least one double bond.
- Examples of cycloalkenyl include cyclopropene, cyclobutene, cyclopentene, cyclohexene, cycloheptene, and the like.
- cycloalkenyl is -C 3-12 cycloalkenyl.
- Cycloheteroalkyl means a monocyclic, bicyclic, spirocyclic, fused or bridged ring or ring system having a specified number of carbon atoms and containing at least one saturated ring wherein at least one ring heteroatom selected from N, NH, S (including SO and SO 2 ) and O, or with at least one partially unsaturated ring wherein at least one ring heteroatom selected from N, NH, S (including SO and SO 2 ) and O.
- the cycloheteroalkyl ring may be substituted on the ring carbons and/or the ring nitrogen or sulfur.
- the cycloheteroalkyl ring may be fused to an aryl or heteroaryl ring.
- cycloheteroalkyl examples include tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, azetidinyl, piperazinyl, piperidinyl, morpholinyl, oxetanyl and tetrahydropyranyl.
- C 2-12 cycloheteroalkyl is selected from: pyrrolidine, piperidine, piperazine, morpholine, oxazepine, hexahydropyrrolo[3,4-b]pyrrole, octahydro-1H- pyrrolo[2,3-c]pyridine, octahydro-1H-pyrrolo[3,4-b]pyridine, octahydro-2H-pyrrolo[2,3- c]pyridine, octahydro-3H-pyrrolo[2,3-c]pyridine, octahydro-1H-indole, octahydro-2H- imidazo[4,5-c]pyridine, octahydrocyclopenta[b]pyrrole, octahydrocyclopenta[c]pyrrole, octahydro-2H-pyrido[3,4-d][1,3]oxazin
- Cycloheteroalkenyl means a monocyclic, bicyclic, spirocyclic, fused, or bridged ring or ring system having a specified number of carbon atoms and containing at least one double bond 25602 and at least one heteroatom selected from N, NH, S (including SO and SO 2 ) and O.
- Examples of cycloheteroalkenyl include dihydropyran and dihydrofuran, and the like.
- Aryl means a monocyclic, bicyclic or tricyclic carbocyclic aromatic ring or ring system containing 6-14 carbon atoms, wherein at least one of the rings is aromatic. Examples of aryl include phenyl and naphthyl.
- aryl is phenyl.
- Heteroaryl means a monocyclic, bicyclic or tricyclic ring or ring system containing 5- 14 ring atoms and containing at least one ring heteroatom selected from N, NH, S (including SO and SO 2 ) and O, wherein at least one of the heteroatom containing rings is aromatic.
- heteroaryl examples include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, dibenzofuranyl, and the like.
- heteroaryl is pyridine or benzofuran. In another embodiment, heteroaryl is pyridine, benzothiophene, or benzofuran. In another embodiment, heteroaryl is pyridine. In another embodiment, heteroaryl is benzofuran. In yet another embodiment, heteroaryl is pyridyl, benzothiophenyl, benzofuranyl or thiophenyl.
- "Halogen" includes fluorine, chlorine, bromine and iodine. In one embodiment, halogen is fluorine, chorine or bromine. In another embodiment, halogen is fluorine or chlorine. In another embodiment, halogen is chlorine or bromine. In another embodiment, halogen is fluorine or bromine.
- a squiggly line across a bond in a substituent variable represents the point of attachment. 25602 Under nomenclature used throughout this disclosure, the point of attachment is described first, followed by the terminal portion of the designated side chain.
- a C 1-5 alkylcarbonylamino C 1-6 alkyl substituent is equivalent to: O - C1-5alkyl - C-NH-C1-6alkyl
- the various e tc. are to be chosen in conformity with well-known principles of chemical structure and stability. The term shall be deemed to include multiple degrees of substitution by a named substitutent.
- the substituted compound can be independently substituted by one or more of the disclosed or claimed substituent moieties, singly or plurally.
- independently substituted it is meant that the (two or more) substituents can be the same or different.
- pharmaceutically acceptable is employed herein to refer to those compounds, materials, compositions, salts and/or dosage forms which are, using sound medical judgment, and following all applicable government regulations, safe and suitable for administration to a human being or an animal.
- Compounds of Formula I may contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers.
- the present disclosure is meant to encompass all such isomeric forms of the compounds of Formula I.
- the independent syntheses of optical isomers and diastereoisomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein.
- Their absolute stereochemistry may be determined by the X- ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration or sufficient heavy atoms to make an absolute assignment. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated.
- the separation can be carried out by methods well-known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereoisomeric mixture, followed by separation of the individual diastereoisomers by standard methods, such as fractional crystallization or chromatography.
- the coupling reaction is often the formation of salts using an enantiomerically pure acid or base.
- the diasteromeric 25602 derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue.
- the racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, which methods are well known in the art.
- any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.
- Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
- Tautomers are defined as compounds that undergo rapid proton shifts from one atom of the compound to another atom of the compound.
- Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of Formula I.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature. Included are all suitable isotopic variations of the compounds of structural formula I.
- different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Tritium is radioactive and may therefore provide for a radiolabeled compound, useful as a tracer in metabolic or kinetic studies.
- Isotopically-enriched compounds within structural formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- some of the crystalline forms for compounds of structural formula I may exist as polymorphs and as such are intended to be included in the present invention.
- some of the compounds of structural formula I may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds structural formula I which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds of structural formula I include, but are not limited to, the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, formic, fumarate, gluceptate, gluconate, glutamate, glycollylars-anilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N- methylglucamine am
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, 25602 cyclic amines, and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- basic ion-exchange resins such as arginine, betaine, caffeine,
- esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
- acyl derivatives of alcohols such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl
- esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
- prodrug means compounds that are rapidly transformed, for example, by hydrolysis in blood, in vivo to the parent compound, e.g., conversion of a prodrug of Formula I to a compound of Formula I, or to a salt thereof; a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol.14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. Prodrugs of the novel compounds of structural formula I are included. Solvates, and in particular, the hydrates of the compounds of structural formula I are included as well.
- Compounds of structural formula I are potent inhibitors of Nod-Like Receptor Protein 3 (NLPR3).
- the compounds, and pharmaceutically acceptable salts thereof, may be efficacious in the treatment of diseases, disorders and conditions that are mediated by the inhibition of Nod- Like Receptor Protein 3 (NLPR3).
- the present disclosure relates to the treatment or prevention of a disease, disorder or condition mediated by NLRP3 such as inflammation, an auto-immune disease, a cancer, an infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a fibrotic disease or fibrosis, a respiratory disease, a kidney disease, a liver disease, an ophthalmic or ocular disease, a skin disease, a lymphatic disease, a rheumatic disease, graft versus host disease, allodynia, or an NLRP3-related disease in a subject that has been determined to carry a germline or somatic non-silent mutation in NLRP3.
- NLRP3 such as inflammation, an auto-immune disease, a cancer, an infection, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a fibrotic disease or fibrosis, a respiratory disease, a kidney disease, a liver disease, an ophthalmic or
- the disease, disorder or condition mediated by NLRP3 includes but is not limited to: gout, pseudogout, osteoarthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease, diabetes, NASH, sepsis, age related macular degeneration, diabetic retinopathy, liver fibrosis, kidney fibrosis, atherosclerosis, heart failure, peripheral artery disease, myeloproliferative neoplasm, leukemia, myelodysplastic syndrome, myelofibrosis, lung cancer, colon cancer, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, hidradenitis suppurativa, pericarditis, myocarditis, preeclampsia, dermatomyositis.
- NLPR3 Nod-Like Receptor Protein 3
- NLPR3 Nod-Like Receptor Protein 3
- diseases, disorders or conditions mediated by Nod-Like Receptor Protein 3 also include, but are not limited to, gout, pseudogout, CAPS, NASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiophathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer’s Disease, Parkinson’s Disease and traumatic brain injury.
- the condition, disease or disorder is an inflammatory joint disease such as gout, pseudogout, or osteoarthritis.
- cryopyrin-associated autoinflammatory syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal onset multisystem inflammatory disease.
- the metabolic disease is diabetes.
- the liver disease is NASH.
- the infection is sepsis.
- the ophthalmic or ocular disease is age related macular degeneration or diabetic retinopathy.
- the fibrotic disease is liver fibrosis or kidney fibrosis.
- the cardiovascular disease is atherosclerosis, heart failure or peripheral artery disease.
- the cancer is myeloproliferative neoplasm, leukemia, myelodysplastic syndrome, myelofibrosis, lung cancer or colon cancer.
- the condition, disease or disorder of the central nervous system is Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, or multiple sclerosis.
- the skin disease is atopic dermatitis or hidradenitis suppurativa (HS).
- the inflammatory disease is pericarditis or myocarditis.
- the inflammatory disease is preeclampsia.
- the rheumatic disease is dermatomyositis.
- the ocular disease is age related macular degeneration, or diabetic retinopathy.
- the kidney disease is an acute kidney disease, a chronic kidney disease, or a rare kidney disease.
- a therapeutically effective amount of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof, to a patient in need of treatment may be treated, managed, prevented, reduced, alleviated, ameliorated or controlled by the administration of a therapeutically effective amount of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof, to a patient in need of treatment.
- the compounds of structural formulae I, Ia and Ib and pharmaceutically acceptable salts thereof may also be used for the manufacture of a medicament which may be useful for treating, preventing, managing, alleviating, ameliorating or controlling one or more of these conditions, diseases or disorders, including but not limited to: gout, pseudogout, osteoarthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disease, diabetes, NASH, sepsis, age related macular degeneration, diabetic retinopathy, liver fibrosis, kidney fibrosis, atherosclerosis, heart failure, peripheral artery disease, myeloproliferative neoplasm, leukemia, myelodysplastic syndrome, myelofibrosis, lung cancer, colon cancer, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, hidradenitis suppurativa, pericarditis
- Still’s disease juvenile idiopathic arthritis, age related macular degeneration, diabetic retinopathy, acute kidney disease, a chronic kidney disease, or a rare kidney disease.
- the compounds of structural formulae I, Ia and Ib and pharmaceutically acceptable salts thereof may also be used for the manufacture of a medicament which may be useful for treating, preventing, managing, alleviating, ameliorating or controlling one or more of these conditions, diseases or disorders, including but not limited to: gout, pseudogout, CAPS, NASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiophathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer’s Disease, Parkinson’s Disease and traumatic brain injury.
- Preferred uses of the compounds may be for the treatment of one or more of the following diseases by administering a therapeutically effective amount to a patient in need of treatment.
- the compounds may be used for manufacturing a medicament for the treatment of one or more of these diseases: (1) gout, (2) pseudogout, (3) cryopyrin-associated periodic syndromes, (4) non-alcoholic steatohepatitis, (5) fibrosis, (6) osteoarthritis, (7) atherosclerosis, (8) atopic dermatitis, (9) hidradenitis suppurativa, (10) Alzheimer’s Disease, and (11) Parkinson’s Disease.
- Treatment of a disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway refers to the administration of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof to a subject with the disease, disorder or condition.
- One outcome of treatment may be reducing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Another outcome of treatment may be alleviating the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Another outcome of treatment may be ameliorating the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Another outcome of treatment may be suppressing the disease, disorder or condition mediated by mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Another outcome of treatment may be managing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Another outcome of treatment may be preventing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway.
- Prevention of the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway refers to the administration of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof to a subject at risk of the disease, disorder or condition.
- One outcome of prevention may be reducing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of the disease, disorder or condition. Another outcome of prevention may be suppressing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of the disease, disorder or condition. Another outcome of prevention may be ameliorating the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of the disease, disorder or condition. Another outcome of prevention may be alleviating the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of the disease, disorder or condition.
- Another outcome of prevention may be managing the disease, disorder or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of the disease, disorder or condition.
- administration of and or “administering a” compound should be understood to mean providing a compound of structural formula I, Ia or Ib or a prodrug of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt of such compound or prodrugto the individual or mammal in need of treatment.
- the administration of the compound of structural formula I in order to practice the present methods of therapy is carried out by administering an effective amount of the compound of structural formula I to the mammal in need of such treatment or prophylaxis.
- the need for a prophylactic administration according to the methods described herein is determined via the use of well known risk factors.
- the effective amount of an individual compound is determined, in the final analysis, by the physician or veterinarian in charge of the case, but depends on factors such as the exact disease to be treated, the severity of the disease and other diseases or conditions from which the patient suffers, the chosen route of administration other drugs and treatments which the patient may concomitantly require, and other factors in the physician's judgment.
- the usefulness of the present compounds in these diseases or disorders may be demonstrated in animal disease models that have been reported in the literature.
- Administration and Dose Ranges Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of structural formula I, Ia or Ib.
- a suitable dosage level will generally be about 0.0001 to 500 mg per kg patient body weight per day which can be administered in single or multiple doses.
- a suitable dosage level may be about 0.001 to 500 mg per kg patient body weight per day. In another embodiment, a suitable dosage level may be about 0.001 to about 250 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.01 to about 250 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.1 to about 100 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.05 to 100 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.1 to 50 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.05 to 0.5 mg/kg per day. In another embodiment, a suitable dosage level may be about 0.5 to 5 mg/kg per day.
- a suitable dosage level may be about 5 to 50 mg/kg per day.
- the compositions are preferably provided in the form of tablets containing 0.01 to 1000 mg of the active ingredient, particularly 0.01, 0.025, 0.05, 0.075, 0.1, 0.25, 0.5, 0.75, 1.0, 2.5, 5.0, 7.5, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 mg of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds may be administered on a regimen of 1 to 8 times per day; preferably, 1 to 4 times a day; more preferably once or twice per day, even more preferably once a day.
- This dosage regimen may be adjusted to provide the optimal therapeutic response. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- the compounds structural formulae I, Ia and Ib may be used in pharmaceutical compositions comprising (a) the compound(s) or pharmaceutically acceptable salts thereof, and (b) a pharmaceutically acceptable carrier.
- the compounds of structural formulae I, Ia and Ib may be used in pharmaceutical compositions in which the compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof is the only active ingredient.
- the compounds of structural formulae I, Ia and Ib may also be used in pharmaceutical compositions that include one or more other active pharmaceutical ingredients.
- composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions described hereinencompass any composition made by admixing a compound of structural formula I, Ia, or Ib or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- Compounds of structural formulae I, Ia and Ib may be used in combination with other drugs that may also be useful in the treatment or amelioration of the diseases or conditions for which compounds of structural formulae I, Ia and Ib are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of structural formula I, Ia or Ib. In the treatment of patients who suffer from chronic inflammatory conditions, more than one drug may be administered.
- the compounds of structural formulae I, Ia and Ib may generally be administered to a patient who is already taking one or more other drugs for these conditions. Often the compounds will be administered to a patient who is already being treated with one or more anti-pain compounds when the patient’s pain is not adequately responding to treatment.
- the combination therapy also includes therapies in which the compound of structural formula I, Ia or Ib and one or more other drugs are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compound of structural formula I, Ia or Ib and the other active ingredients may be used in lower doses than when each is used singly. Accordingly, the pharmaceutical compositions of the present disclosure include those that contain one or more other active ingredients, in addition to a compound of structural formula I, Ia or Ib.
- Examples of other active ingredients that may be administered in combination with a compound of structural formula I, Ia or Ib , and either administered separately or in the same pharmaceutical composition include but are not limited to: (i) anti-steatotic agents; (ii) anti-inflammatory agents; (iii) immunooncology agent; (iv) lipid-lowering agents; (v) cholesterol lowering agents; 25602 (vi) glucose-lowering agents, including SGLT2 inhibitors; (vii) anti-neovascular agents; (viii) nonsteroidal anti-inflammatory drugs ("NSAIDs"); (ix) acetyl-salicylic acid drugs (ASA) including aspirin; paracetamol; (x) regenerative therapy treatments; (xi) checkpoint inhibitors including anti-PD1 and anti-PDL1 inhibitors; (xii) checkpoint inhibitors including anti-PD1 and anti-PDL1 inhibitors; (xii) checkpoint inhibitors including anti-PD1 and anti-PDL1 inhibitors; (xii) checkpoint inhibitors including
- the pharmaceutical composition comprises: (1) a compound of structural formula I, Ia or Ib, or a pharmaceutically acceptable salt thereof; (2) one or more compounds, or pharmaceutically acceptable salts thereof, selected from the group: (i) anti-steatotic agents; (ii) anti-inflammatory agents; (iii) immunooncology agent; (iv) lipid-lowering agents; (v) cholesterol lowering agents; (vii) glucose-lowering agents, including SGLT2 inhibitors; (vii) anti-neovascular agents; (viii) nonsteroidal anti-inflammatory drugs ("NSAIDs"); (ix) acetyl-salicylic acid drugs (ASA) including aspirin; paracetamol; (x) regenerative therapy treatments; (xi) checkpoint inhibitors including anti-PD1 and anti-PDL1 inhibitors; (xii) chemotherapy procedures; (xiii) radiation therapy; (xiv) surgical procedures; (xv) urate-lowering therapy; (xvi) anabolics and cartilage regenerative therapy;
- anti-steatotic agents including but not limited to, DGAT2 inhibitors.
- Suitable anti-inflammatory agents include, but are not limited to, TNF ⁇ inhibitors, JAK inhibitors and NSAIDs.
- Suitable lipid-lowering agents include, but are not limited to statins and PCSK9.
- Suitable immunooncology agents include, but are not limited to, PD-L1 inhibitors and PD-1 inhibitors and STING antagonists.
- Suitable glucose-lowering agents include, but are not limited to, insulin, SGLT2 inhibitors, metformin, GLP1-agonists.
- Suitable anti-neovascular agents include, but are not limited to, anti-VEG-F treatment.
- Suitable NSAIDs or non-steroidal anti-inflammatory drugs include, but are not limited to, aspirin, diclofenac, diflunisal, etodolac, fenoprofin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamic acid, mefenamic acid, meloxicam, naproxen, naproxen sodium, oxaprozin, piroxicam, sulindac, and tolmetin.
- Suitable analgesics include, but are not limited to, acetaminophen and duloxetine.
- the above combinations include combinations of a compound of structural formula I, Ia or Ib or a pharmaceutically acceptable salt thereof not only with one other active compound, but also with two or more other active compounds.
- Non-limiting examples include combinations of compounds with two or more active compounds selected from: anti-steatotic agents, anti-inflammatory agents, lipid-lowering agents, anti-fibrosis, immunooncology agents, glucose- lowering agents and anti-neovascular agents, NSAIDs (non-steroidal anti-inflammatory drugs), and an analgesics.
- a method for the treatment or prevention of a NLRP3 mediated disease, disorder or condition comprises administration to a patient in need of such treatment or at risk of developing a NLRP3 mediated disease with a therapeutically effective amount of a NLRP3 inhibitor and an amount of one or more active ingredients, such that together they give effective relief.
- a pharmaceutical composition comprising a NLRP3 inhibitor and one or more active ingredients, together with at least one pharmaceutically acceptable carrier or excipient.
- a product comprising a NLRP3 inhibitor and one or more active ingredients as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of an NLRP3-mediated disease, disorder or condition.
- a combined preparation may be, for example, in the form of a twin pack.
- a compound of structural formula I, Ia or Ib may be used in conjunction with another pharmaceutical agent effective to treat that disease, disorder or conditon.
- a method for the treatment or prevention of chronic inflammatory conditions comprises administration to a patient in need of such treatment an amount of a compound structural formula I, Ia, or Ib or a pharmaceutically acceptable salt thereof and an amount of another pharmaceutical agent effective to threat that disorder, disease or condition, such that together they give effective relief.
- a method for the treatment or prevention of chronic inflammatory conditions comprises administration to a patient in need of such treatment an amount of a compound structural formula I, Ia, or Ib ora pharmaceutically acceptable salt thereof and an amount of another pharmaceutical agent useful in treating that particular condition, disorder or disease, such that together they give effective relief.
- terapéuticaally effective amount means the amount the compound of structural formula I (or Ia or Ib) that will elicit the biological or medical response of a cell, tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disorder being treated.
- the novel methods of treatment disclosed herein are for disorders known to those skilled in the art.
- the term “mammal” includes humans, and companion animals such as dogs and cats.
- the weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used.
- the weight ratio of the compound of the Formula I generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200.
- Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.
- LC/MS determinations were carried out on Waters ACQUITY UPLC equipped with a DAD and QDa MS detectors using the following conditions: Waters ACQUITY UPLC BEH C18 1.7mm 2.1x50mm column using mobile phase containing A: 0.1% TFA in water and B: 0.1% TFA in acetonitrile with a gradient from 10% B to 90% B over 2.0 min and hold at 90%B for 0.4 min at a flow rate of 0.5 mL/min.
- Proton or 1 H NMR was acquired using a Bruker 500 MHz NEO NMR spectrometer equipped with a 5mm iProbe in accordance with standard analytical techniques, unless specified otherwise, and results of spectral analysis arereported.
- DFMS Bis(((difluoromethyl)-sulfinyl)oxy)zinc
- DIC N,N′-diisopropyl-carbodiimide
- DAST diethylaminosulfur trifluoride
- DCE dichloroethane
- DCM dichloromethane
- dd is doublet of doublets
- DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone
- Dess-Martin Periodinane is 1,1,1- tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one
- dqd is doublet of a quartet of doublets
- DEA diethanolamine
- DIPEA is N,N-diisopropylethylamine
- DMA is dimethyl-acetamide
- DMAP dimethylamino pyridine
- DME dimethoxyethane
- Scheme B Scheme B amines, such as B-3, from Boc-protected amines, such as B-1. Reductive amination of free amine B-1 followed by Boc deprotection affords selectively substituted amine derivatives such as B-3. 25602 Scheme C as C-4.
- SNAr regioselective nucleophilic aromatic substitution
- Step 2 2-Iodo-3-methyl-5-(trifluoromethyl)phenol: NaH (128.5 g, 3.21 mol, 60 wt%) was added at 0 o C to a stirring solution of 3-methyl-5-(trifluoromethyl)phenol (283 g, 1.61 mol) in toluene (1.42 L) under N2 atmosphere. The resulting mixture was stirred at 0°C for 30 min, followed by the portion wise addition of a solution of I 2 (306.1 g, 1.21 mmol) in toluene (5.66 L). The resulting mixture was stirred at 20 °C for 3 h, then quenched by pouring onto a water/ice bath. The mixture was diluted with EtOAc, and the layers were separated.
- Step 3 1-(Ethoxymethoxy)-2-iodo-3-methyl-5-(trifluoromethyl)benzene: Chloromethyl ethyl ether (289.9 g, 3.07 mol) was added at 0 o C to a stirring solution of 2-iodo-3-methyl-5- (trifluoromethyl)phenol (463 g, 1.53 mol) and Cs2CO3 (998.9 g, 3.07 mmol) in DMF (4.6 L) under a N 2 atmosphere.
- Step 4 2-(2-(Ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane: A mixture containing 1-(ethoxymethoxy)-2-iodo-3-methyl-5- (trifluoromethyl)benzene (330 g, 916.4 mmol), B 2 pin 2 (469.1 g, 3.67 mol), Et 3 N (556.4 g, 5.50 mol), Pd(OAc)2 (10.3 g, 45.8 mmol), and (2-biphenyl)dicyclohexylphosphine (32.1 g, 91.6 mmol) in 1,4-dioxane (3.3 L) was placed under N 2 atmosphere.
- the reaction mixture was stirred for 6 h at 100 o C, then cooled to 25 o C and quenched with ice water. The resulting mixture was filtered, and the solid residue was washed with EtOAc. The filtrate layers were separated. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The resulting crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) and the solvent was removed under vacuum. The resulting solid was dissolved in hexanes and stirred for 5 min at –30 o C. Then the precipitated solids were collected 25602 by filtration to afford the title compound.
- Step 2 tert-butyl (3aS,7R,7aR and 3aR,7S,7aS)-7-hydroxyoctahydro-1H-indole-1-carboxylate: To a solution of tert-butyl (3aS,7aR and 3aR,7aS)-7-oxooctahydro-1H-indole-1-carboxylate (240 mg, 1 mmol) in MeOH (5 mL) at 0 °C was added NaBH4 (190 mg, 5 mmol). The mixture was warmed to room temperature and stirred for 2 h. The solvent was removed under reduced pressure, and the resulting crude residue was diluted with EtOAc and H 2 O.
- reaction mixture was heated to 100 °C and stirred for 12 h. Then the reaction mixture was allowed to cool to room temperature, and diluted with H 2 O and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (x3). Combined organic layers were dried over MgSO 4 , filtered and the solvent was removed under reduced pressure. The resulting crude residue was purified by silica gel chromatography (EtOAc:hexanes) to afford a racemic mixture of the title compounds.
- the reaction mixture was warmed to room temperature and stirred for 2 h. Then the reaction was quenched with a saturated solution of NH 4 Cl, and diluted with H 2 O and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (x3). The combined organic layers were dried over MgSO 4 , filtered and the solvent was removed under vacuum. The resulting residue was dissolved in THF (1.0 mL), and a solution of DDQ (1 mL, 0.2 mmol, 0.2 M in THF) was added. The reaction mixture was stirred at room temperature for 12 h.
- the reaction mixture was heated to 25602 50°C and stirred for 16 h, followed by cooling to room temperature.
- the resulting crude mixture filtered, and purified by reverse phase HPLC (C18 stationary phase, MeCN/H2O + 0.1% TFA).
- the product fractions were combined, diluted with EtOAc and basified with saturated NaHCO 3 solution.
- the layers were separated, and the aqueous layer was extracted with EtOAc (x3).
- the combined organic layers were dried over MgSO4, filtered, and solvents removed under reduced pressure to afford the title compound.
- reaction mixture was cooled to –78 o C, followed by addition of AcOH (9.4 mL, 165 mmol) and H 2 O 2 (3.83 mL, 165 mmol) over 15 min, then warmed to room temperature and stirred for 12 h.
- the reaction mixture was then diluted with a saturated aqueous NH4Cl, a saturated aqueous solution of Na 2 SO 3 , H 2 O, and DCM.
- the layers were separated and the aqueous phase was extracted with DCM (x2).
- the combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- the resulting crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to afford the title compound.
- Step 2 1-bromo-2-(ethoxymethoxy)-3-fluoro-4-(trifluoromethyl)benzene: To a solution of 6- bromo-2-fluoro-3-(trifluoromethyl)phenol (7.9 g, 30.5 mmol) in DMF (70 mL), were added (chloromethoxy)ethane (4.24 mL, 45.8 mmol) and Cs 2 CO 3 (14.9 g, 45.8 mmol).
- Step 3 2-(2-(ethoxymethoxy)-3-fluoro-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane: To a solution of 2-bromo-3-(ethoxymethoxy)-4-fluoro-1-methyl-5- (trifluoromethyl)benzene (300 mg, 0.91 mmol) in 1,4-dioxane (8 mL) were added 4,4,5,5- tetramethyl-1,3,2-dioxaborolane (0.53 mL, 3.6 mmol), Et3N (0.71 mL, 5.4 mmol), Pd(OAc)2 (10.2 mg, 0.045 mmol), and 2-(dicyclohexylphosphino)biphenyl (31.8 mg, 0.091 mmol).
- Step 2 2-(2-methoxy-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2- dioxaborolane: To a solution of 2-iodo-1-methoxy-3-methyl-5-(trifluoromethyl)benzene (1.5 g, 4.75 mmol) in 1,4-dioxane (12 mL) were added 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.43 g, 19.0 mmol), Et3N (4.0 mL, 28.5 mmol), Pd(OAc)2 (107 mg, 0.48 mmol), and 2- (dicyclohexylphosphino)biphenyl (333 mg, 0.95 mmol).
- Step 3 (2-methoxy-6-methyl-4-(trifluoromethyl)phenyl)boronic acid: NH4OAc (1.23 g, 15.9 mmol) and NaIO4 (3.41 g, 15.9 mmol) was added to a solution of 2-(2-methoxy-6-methyl-4- (trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.26 g, 3.99 mmol) in acetone (5 mL) and water (5 mL). The resulting reaction mixture was stirred at room temperature for 12 h. Then the reaction mixture was diluted with H 2 O and EtOAc.
- Step 2 tert-butyl 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate: Pd/C (34.3 mg, 0.32 mmol) was added to a solution of tert-butyl 5-methoxy-1H-pyrrolo[2,3-c]pyridine-1- carboxylate (400 mg, 1.6 mmol) in MeOH (10 mL). The reaction mixture was stirred at 70 °C for 16 h under H2 (15 psi).
- Step 4 (3aR,7aR)-octahydro-5H-pyrrolo[2,3-c]pyridin-5-one and (3aS,7aS)-octahydro-5H- pyrrolo[2,3-c]pyridin-5-one: PtO 2 (105 mg, 0.46 mmol) was added to a solution of 2,3-dihydro- 25602 1H-pyrrolo[2,3-c]pyridin-5-ol (210 mg, 1.5 mmol) in AcOH (10 mL).
- Step 2 5-chloro-2-(5-methyl-3-((3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)- 1,2,4-triazin-6-yl)phenol: HCl 0.92 mmol, 4 M in 1,4-dioxane) was added to a solution of (3aS,7aR)-1-(6-(4-chloro-2- phenyl)-5-methyl-1,2,4-triazin-3-yl)-6- methyloctahydro-1H-pyrrolo[2,3-c]pyridine (37 mg, 0.09 mmol) in 1,4-dioxane (0.92 mL).
- the mixture was degassed with N2 for 10 min and stirred at 100 °C for 15 h. Then additional cyclopropylboronic acid (24 mg, 0.28 mmol), tricyclohexyl- phosphine (52 mg, 0.19 mmol), and Pd(OAc)2 (4.2 mg, 0.02 mmol) were added.
- the reaction degassed with N2 and stirred at 100 °C for 8 h. Then the reaction mixture was cooled to room temperature and diluted with H2O and EtOAc. The layers were separated, and the aqeuous layer extracted with EtOAc (x3).
- Example 72 2-(3-((3aS,7aR)-6-ethyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)-5-methyl-1,2,4-triazin-6-yl)-5- (trifluoromethyl)phenol
- 2-(5-methyl-3-( [2,3-c]pyridin-1-yl)-1,2,4- triazin-6-yl)-5-(trifluoromethyl) mg, 0.1 mmol) in MeOH (1 mL) at 0 °C was added acetaldehyde (60 ⁇ L, 1.0 mmol), followed by NaBH(OAc) 3 (64 mg, 0.3 mmol).
- Examples 73 and 74 3-methyl-2-(3-((3aS,7aR or 3aR,7aS)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)-1,2,4- yl)-5-(trifluoromethyl)phenol (Example 73, Peak 1), and 3-methyl-2- or 3aS,7aR)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)-1,2,4- 6-yl)-5-(trifluoromethyl)phenol (Example 74, Peak 2)
- reaction mixture was warmed up to room temperature and stirred for 2 h. Then the solvent was were removed under reduced pressure and crude mixture was purified by reverse phase HPLC (C18 stationary phase, MeCN/H 2 O + 0.1% TFA) to afford the racemic 25602 mixture of the title compounds.
- Example Structure Name LCMS Chiral [M+H] + Method a e . e o owng compoun was prepare usng a proceure sm ar o e proceure or Example 67 using the appropriate starting materials.
- reaction mixture was then cooled to 0 °C and quenched by the dropwise addition of saturated aqueous NaHCO3.
- the resulting mixture was diluted with DCM, the layers separated and the aqueous phase was extracted with DCM (x2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure.
- the resulting crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to afford the title compound.
- Step 2 (3aS,7aR and 3aR,7aS)-1-(6-(4-(1,1-difluoroethyl)-2-methoxyphenyl)-5-methyl-1,2,4- triazin-3-yl)-6-methyloctahydro-1H-pyrrolo[2,3-c]pyridine: A solution of 2,2'-bipyridine (11.8 mg, 0.076 mmol) and NiCl2DME (16.6 mg, 0.076 mmol) in DMA (1 mL) was stirred at 50 °C for 30 min under a N 2 atmosphere.
- reaction mixture was then heated to 140 °C, and stirred for 2 h. Then the reaction mixture was cooled to room temperature, and diluted with H2O and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (x2). The combined organic layers were dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The resulting crude residue was purified by reverse phase HPLC (C18 stationary phase, MeCN/H 2 O + 0.05% NH 4 OH + 10mM NH 4 HCO 3 ) to afford the racemic mixture of the title compounds.
- a 100 mg potency tablet is composed of 100 mg of any one of the Examples, 268 mg microcrystalline cellulose, 20 mg of croscarmellose sodium, and 4 mg of magnesium stearate. The active, microcrystalline cellulose, and croscarmellose are blended first. The mixture is then lubricated by magnesium stearate and pressed into tablets. BIOLOGICAL ASSAY 25602 Activation of the canonical NLRP3 inflammasome requires two steps, priming and activation.
- a priming signal such as a pathogen activated molecular patterns (PAMPs) or danger- activated molecular patterns (DAMPs) are recognized by Toll-like receptors leads to nuclear factor kappa B (NF-KB)-mediated signaling. This in turn, up-regulates transcription of inflammasome-related components, including inactive NLRP3 and prolL-1 ⁇ (Bauernfeind et al., J. Immunol.2009, 183, 787 - 791; Franchi et al., Nat. Immunol.2012, 13, 325 - 332; Franchi et al., J. Immunol.2014, 193, 4214 - 4222).
- PAMPs pathogen activated molecular patterns
- DAMPs danger- activated molecular patterns
- the second step is activation which induces oligomerization of NLRP3 and subsequent assembly of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and procaspase-1 into an inflammasome complex.
- ASC apoptosis-associated speck-like protein containing a CARD
- procaspase-1 into an inflammasome complex.
- This triggers the transformation of procaspase-1 to caspase-1, and the production and secretion of mature IL-1 ⁇ and IL-18 (Kim et al., J. Inflamm.2015, 12, 41; Ozaki et al., J. Inflamm. Res.2015, 8, 15 - 27; Rabeony et al., Eur. J. Immunol.2015, 45, 2847).
- ASC SPECK an event commonly referred to as “ASC SPECK” formation as it is identified in the cell as a discrete puncta within the cell after staining and visualization of ASC using common immunocytochemical methods.
- ASC SPECK an event commonly referred to as “ASC SPECK” formation as it is identified in the cell as a discrete puncta within the cell after staining and visualization of ASC using common immunocytochemical methods.
- the ability of compounds to inhibit NLRP3 inflammasome activation was determined in vitro by monitoring formation of the ASC-SPECK in human monocytic THP-1 cells after stimulation.
- THP-1 cells (ATCC catalog #TIB-202) were maintained in complete growth media containing Roswell Park Memorial Institute RPMI (ATCC catalog #30-2001), 10% heat inactivated fetal bovine serum, 1X penicillin/streptomycin and 0.05mM 2-mercaptoethanol.
- undifferentiated THP-1 cells were plated at a density of 20,000 cells per well in a 384-well plate (Poly-D-lysine coated Cell Carrier Ultra microplate, Perkin Elmer catalog #6057500) in complete growth media supplemented with 10 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma catalog #P8139), and then incubated overnight. The next day, media was replaced with assay media [RPMI (Gibco catalog #11875-093), 0.01% bovine serum albumin (BSA)].
- PMA phorbol 12-myristate 13-acetate
- Cells 25602 were first permeabilized with 0.3% Triton X-100 in phosphate-buffered saline (PBS) for 15 minutes and then incubated in blocking buffer containing 5% goat serum, 0.3% tween-20 and 0.03% sodium azide in PBS for 1 hour. Cells were stained with a mixture of ASC-Alexa 488 antibody (diluted 1:200 in blocking buffer) and nuclear stain DRAQ5 (1:5000 in blocking buffer, Thermo catalog #62251) in blocking buffer for 1 hour. Following a wash with 0.3% Tween-20 in PBS, plates were imaged with an Opera Phenix High Content Screening System. The number of DRAQ5 positive cells containing ASC SPECKS were quantified in each well.
- PBS phosphate-buffered saline
- EC 50 values were calculated by standard curve-fitting analysis using an internally developed program in TIBCO Spotfire software.
- the compounds of structural formula I inhibit NLRP3 inflammasome activation in the above Biological Assay and have EC50 values of less than 5 micromolar.
- Specific EC50 values of the compounds of Examples 1-106 in the above Biological Assay are listed in Table I. Table I.
- effective dosages other than the particular dosages as set forth herein above may be applicable as a consequence of variations in responsiveness of the mammal being treated for any of the indications with the compounds of structural formulae I, Ia, Ib and pharmaceutically acceptable salts thereof.
- the specific pharmacological responses observed may vary according to and depending upon the particular compounds selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present disclosure. It should be understood that various alternatives to the embodiments of the present disclosure described herein may be employed in practicing the methods and uses disclosed herein. .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
De nouveaux composés de formule structurale I, et leurs sels pharmaceutiquement acceptables, sont des inhibiteurs de NLRP3 et peuvent être utiles dans le traitement, la prévention, la gestion, le soulagement, le contrôle et la suppression de maladies médiées par NLPR3. Ces composés peuvent être utiles dans le traitement, la prévention ou la gestion de maladies, de troubles et d'états médiés par NLRP3 tels que, mais de façon non limitative, la goutte, la pseudo-goutte, le CAPS, la fibrose NASH, l'insuffisance cardiaque, la péricardite idiopathique, la dermatite atopique, la maladie intestinale inflammatoire, la maladie d'Alzheimer, la maladie de Parkinson et la lésion cérébrale traumatique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263421620P | 2022-11-02 | 2022-11-02 | |
US63/421,620 | 2022-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024097598A1 true WO2024097598A1 (fr) | 2024-05-10 |
Family
ID=90931422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/077986 WO2024097598A1 (fr) | 2022-11-02 | 2023-10-27 | Triazines utiles comme inhibiteurs de la protéine réceptrice de type nod 3 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024097598A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207985A1 (en) * | 2006-03-01 | 2007-09-06 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
WO2013092244A1 (fr) * | 2011-12-20 | 2013-06-27 | Basf Se | Triazines herbicides |
WO2019141552A1 (fr) * | 2018-01-18 | 2019-07-25 | Basf Se | Composés herbicides de triazine |
WO2019191229A1 (fr) * | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Composés permettant de traiter la maladie de huntington |
WO2020234715A1 (fr) * | 2019-05-17 | 2020-11-26 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
-
2023
- 2023-10-27 WO PCT/US2023/077986 patent/WO2024097598A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207985A1 (en) * | 2006-03-01 | 2007-09-06 | Bristol-Myers Squibb Company | Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors |
WO2013092244A1 (fr) * | 2011-12-20 | 2013-06-27 | Basf Se | Triazines herbicides |
WO2019141552A1 (fr) * | 2018-01-18 | 2019-07-25 | Basf Se | Composés herbicides de triazine |
WO2019191229A1 (fr) * | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Composés permettant de traiter la maladie de huntington |
WO2020234715A1 (fr) * | 2019-05-17 | 2020-11-26 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
Non-Patent Citations (1)
Title |
---|
DATABASE PUBCHEM COMPOUND 19 May 2008 (2008-05-19), ANONYMOUS: "3-Cyclopropyl-5-methyl-6-phenyl-1,2,4-triazine", XP093172019, Database accession no. 24784897 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017323584B2 (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
JP6878615B2 (ja) | Shp2阻害剤として有用な新規な複素環式誘導体 | |
JP7323723B2 (ja) | Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド | |
AU2021292062A1 (en) | 5-oxopyrrolidine-3-carboxamides as Nav1.8 inhibitors | |
JP2021507912A (ja) | 6−アザインドール化合物 | |
AU2021292061A1 (en) | 2-oxo-oxazolidine-5-carboxamides as Nav1.8 inhibitors | |
AU2013208968A1 (en) | Substituted annulated pyrimidines and triazines, and use thereof | |
JP2023522016A (ja) | Nlrp3インフラマソーム経路の阻害剤としてのピラゾロ[1,5-d][1,2,4]トリアジン-5(4h)-アセトアミド | |
CA2932870C (fr) | Derives de [1,2,4]triazolo[1,5-a]pyrimidine utilises comme inhibiteurs du proteasome des protozoaires pour le traitement de maladies parasitaires comme la leishmaniose | |
CN115485280A (zh) | 新三嗪并吲哚化合物 | |
WO2016065582A1 (fr) | Inhibiteurs du canal potassique médullaire externe rénal | |
IL303779A (en) | CDK inhibitors and their use as drugs | |
WO2022194192A1 (fr) | Composé hétéroaromatique, son procédé de préparation et son utilisation | |
WO2022194906A1 (fr) | Composés antibactériens | |
TWI787857B (zh) | 吡唑并[1,5-a]吡啶類化合物及其製備方法和應用 | |
TWI779487B (zh) | 二氫萘啶酮類化合物,其製法與醫藥上的用途 | |
AU2012226251A1 (en) | (--)- huperzine A processes and related compositions and methods of treatment | |
WO2024097598A1 (fr) | Triazines utiles comme inhibiteurs de la protéine réceptrice de type nod 3 | |
WO2024064245A1 (fr) | Derives de phtalazine utiles en tant qu'inhibiteurs de la proteine receptrice de type nod 3 | |
WO2024137319A1 (fr) | Hétérocyles bicycliques 6,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3 | |
WO2023138637A1 (fr) | Composé d'acide phosphonique et promédicament de celui-ci, procédés de préparation et utilisations d'un composé d'acide phosphonique et d'un promédicament de celui-ci | |
WO2024180499A1 (fr) | Dérivés d'hydroquinazoline pour le traitement d'une maladie ou d'un trouble | |
JP2023538097A (ja) | ピリミジノン化合物およびその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23886839 Country of ref document: EP Kind code of ref document: A1 |